One-Pot Van Leusen Synthesis
of 4,5-Disubstituted Oxazoles in Ionic Liquids

Bo Wu; Jun Wen; Ji Zhang; Jing Li; Yong-Zhe Xiang; Xiao-Qi Yu

doi:10.1055/s-0028-1087547

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2009(3): 500-504
DOI: 10.1055/s-0028-1087547

LETTER

One-Pot Van Leusen Synthesis of 4,5-Disubstituted Oxazoles in Ionic Liquids

Bo Wu, Jun Wen, Ji Zhang, Jing Li, Yong-Zhe Xiang, Xiao-Qi Yu*
Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. of China
Fax: +86(28)85415886; e-Mail: xqyu@scu.edu.cn;

Further Information

Publication History

Received 8 October 2008
Publication Date:
21 January 2009 (online)

Abstract
Full Text
References
Supplementary Material

Permissions and Reprints All articles of this category

Abstract

An efficient and mild protocol for the preparation of 4,5-disubstituted oxazoles through an improved one-pot van Leusen oxazole synthesis in ionic liquids is described. The oxazole products were prepared from tosylmethyl isocyanide (TosMIC), aliphatic halides and various aldehydes in high yields. The recovered ionic liquids could be reused as solvent for six runs without significant loss of yields.

Key words

ionic liquids - van Leusen oxazole synthesis - tosylmethyl isocyanide - halides - aldehydes

Supporting Information

References and Notes

1a Wipf P. Chem. Rev. 1995, 95: 2115

Google Scholar
1b Janvier P. Sun X. Bienayme H. Zhu J. J. Am Chem. Soc. 2002, 124: 2560

Google Scholar
1c Ikemoto N. Miller RA. Fleitz FJ. Liu J. Petrillo DE. Leone JF. Laquidara J. Marcune B. Karady S. Armstrong JD. Volante RP. Tetrahedron Lett. 2005, 46: 1867

Google Scholar
2a Turchi IJ. Dewar MJS. Chem. Rev. 1975, 75: 389

Google Scholar
2b Wasserman HH. McCarthy KE. Prowse KS. Chem. Rev. 1986, 86: 845

Google Scholar
2c Yeh VSC. Tetrahedron 2004, 60: 11995

Google Scholar
2d Martin R. Cuenca A. Buchwald SL. Org. Lett. 2007, 9: 5521

Google Scholar
2e Herrera A. Martinez-Alvarez R. Ramiro P. Molero D. Almy J. J. Org. Chem. 2006, 71: 3026

Google Scholar
2f Davies JR. Kane PD. Moody CJ. Tetrahedron 2004, 60: 3967

Google Scholar
3a Brahma S. Ray JK. J. Heterocycl. Chem. 2008, 45: 311

Google Scholar
3b Li B. Buzon RA. Zhang ZJ. Org. Process Res. Dev. 2007, 11: 951

Google Scholar
3c Baumann M. Baxendale IR. Ley SV. Smith CD. Tranmer GK. Org. Lett. 2006, 8: 5231

Google Scholar
3d Miller RA. Smith RM. Marcune B. J. Org. Chem. 2005, 70: 9074

Google Scholar
3e Davies JR. Kane PD. Moody CJ. Tetrahedron 2004, 60: 3967

Google Scholar
3f Xia Q. Ganem B. Synthesis 2002, 1969

Google Scholar
3g Ohba M. Kubo H. Seto S. Fujii T. Ishibashi H. Chem. Pharm. Bull. 1998, 46: 860

Google Scholar
3h Matsumoto K. Suzuki M. Yoneda N. Miyoshi M. Synthesis 1976, 805

Google Scholar
3i Possel O. Van Leusen A. Heterocycles 1977, 7: 77

Google Scholar
3j van Leusen AM. Hoogenboom BE. Siderius H. Tetrahedron Lett. 1972, 13: 2369

Google Scholar
For reviews, see:
4a Welton T. Chem. Rev. 1999, 99: 2071

Google Scholar
4b Wasserscheid P. Keim W. Angew. Chem. Int. Ed. 2000, 39: 3772

Google Scholar
4c Parvulescu VI. Hardacre C. Chem. Rev. 2007, 107: 2615

Google Scholar
4d van Rantwijk F. Sheldon RA. Chem. Rev. 2007, 107: 2757

Google Scholar
4e Martins MAP. Frizzo CP. Moreira DN. Zanatta N. Bonacorso HG. Chem. Rev. 2008, 108: 2015

Google Scholar
4f de Maria PD. Angew. Chem. Int. Ed. 2008, 47: 2

Google Scholar
6 van Leusen AM. Boerma GJM. Helmholdt RB. Siderius H. Strating J. Tetrahedron Lett. 1972, 2367

Crossref Google Scholar
7 Sisko J. Mellinger M. Sheldrake PW. Baine NH. Tetrahedron Lett. 1996, 37: 8113

Crossref Google Scholar
8 van Leusen AM. Bouma RJ. Possel O. Tetrahedron Lett. 1975, 3487

Crossref Google Scholar

5

Wu B., Zhang J., Zheng Z.-G., Yang M., Yu X.-Q.; Chin. J. Chem.; 2008, in press

9

Representative Preparation of Monosubstituted TosMIC: 1-Bromobutane (5a; 0.206 g, 1.5 mmol) was added to the mixture of TosMIC (4; 0.195 g, 1 mmol), K₂CO₃ (0.414 g, 3 mmol) and [bmim]Br (2.5 mL). After vigorous stirring for 12 h at r.t., the mixture was poured into H₂O (10 mL), and was extracted with Et₂O (3 × 10 mL). The combined organics were washed with H₂O and brine. The organic phase was dried over Na₂SO₄, and concentrated in vacuum. The crude product was purified by chromatography on silica gel (PE-EtOAc, 4:1) to provide pure compound 2a (95%).

10

Representative Preparation of 4,5-Disubstituted Oxazoles: 1-Bromobutane (5a; 0.206 g, 1.5 mmol) was added to the mixture of TosMIC (4; 0.195 g, 1 mmol), K₂CO₃ (0.414 g, 3 mmol) and [bmim]Br (2.5 mL). After vigorous stirring 12 h at r.t., 4 was consumed, and benzaldehyde (6a; 0.127 g, 1.2 mmol) was added. After about 10 h of stirring, the mixture was poured into H₂O (10 mL), and was extracted with Et₂O (3 × 10 mL). The combined organics were washed with H₂O and brine. The organic phase was dried over Na₂SO₄, and concentrated in vacuum. The crude product was purified by chromatography on silica gel (PE-EtOAc, 10:1) to provide pure compound 7a (85%).

11

Spectroscopic Data for Products:
Compound 2a: ^¹H NMR (400 MHz, CDCl₃): δ = 0.91-0.95 (t, J = 14.4 Hz, 3 H), 1.33-1.49 (m, 3 H), 1.56-1.65 (m, 1 H), 1.79-1.88 (m, 1 H), 2.15-2.21 (m, 1 H), 2.48 (s, 3 H), 4.43-4.46 (m, 1 H), 7.41-7.44 (d, J = 8.0 Hz, 2 H), 7.85-7.87 (d, J = 8.4 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.7, 21.8, 21.8, 27.4, 28.2, 73.0, 130.1, 130.2, 131.2, 146.6, 164.9.
Compound 2b: ^¹H NMR (400 MHz, CDCl₃): δ = 1.74-1.75 (d, J = 6.8 Hz, 3 H), 2.50 (s, 3 H), 4.60-4.65 (m, 1 H), 7.44-7.46 (d, J = 8.0 Hz, 2 H), 7.87-7.89 (d, J = 8.0 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 15.5, 21.8, 68.3, 130.2, 130.7, 146.7, 164.6.
Compound 2c: ^¹H NMR (400 MHz, CDCl₃): δ = 1.16-1.19 (t, J = 15.2 Hz, 3 H), 1.84-1.92 (m, 1 H), 2.23-2.29 (m, 1 H), 2.49 (s, 3 H), 4.38-4.42 (m, 1 H), 7.42-7.44 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.4 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 9.9, 21.8, 22.5, 74.2, 130.0, 130.2, 131.3, 146.6, 164.9.
Compound 2d: ^¹H NMR (400 MHz, CDCl₃): δ = 0.86-0.90 (t, J = 13.6 Hz, 3 H), 1.27-1.37 (m, 10 H), 1.40-1.48 (m,
1 H), 1.58-1.65 (m, 1 H), 1.78-1.88 (m, 1 H), 2.14-2.22 (m, 1 H), 2.49 (s, 3 H), 4.43-4.47 (m, 1 H), 7.42-7.44 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.4 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 14.3, 22.0, 22.8, 25.6, 28.6, 28.8, 29.2, 29.3, 31.9, 73.2, 130.3, 130.3, 131.4, 146.7, 165.1.
Compound 2e: ^¹H NMR (400 MHz, CDCl₃): δ = 2.49 (s, 3 H), 2.96-3.02 (m, 1 H), 3.58-3.62 (m, 1 H), 4.58-4.61 (m, 1 H), 7.26-7.27 (m, 2 H), 7.29-7.37 (m, 3 H), 7.43-7.45 (d, J = 8.0 Hz, 2 H), 7.90-7.92 (d, J = 8.4 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 21.8, 34.8, 74.2, 128.1, 129.1, 129.3, 130.2, 130.2, 131.2, 133.3, 146.8, 166.0.
Compound 2f: ^¹H NMR (400 MHz, CDCl₃): δ = 2.49 (s,
3 H), 2.53-2.61 (m, 1 H), 2.95 (s, 1 H), 4.47-4.51 (m, 1 H), 5.28-5.33 (m, 2 H), 5.73-5.83 (m, 1 H), 7.43-7.45 (d, J = 8.0 Hz, 2 H), 7.87-7.89 (d, J = 8.4 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 21.8, 21.8, 29.7, 33.1, 72.3, 121.3, 121.4, 129.3, 130.2, 131.1, 146.7, 165.5.
Compound 2g: ^¹H NMR (400 MHz, CDCl₃): δ = 1.16-1.18 (d, J = 6.8 Hz, 3 H), 1.21-1.22 (d, J = 6.4 Hz, 3 H), 2.48 (s, 3 H), 2.70-2.77 (m, 1 H), 4.33-4.34 (d, J = 3.6 Hz, 1 H), 7.41-7.43 (d, J = 8.0 Hz, 2 H), 7.86-7.88 (d, J = 8.0 Hz, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 16.9, 20.8, 27.9, 30.9, 78.0, 129.6, 130.2, 133.0, 146.4, 165.5.
Compound 7a: ^¹H NMR (400 MHz, CDCl₃): δ = 0.93-0.97 (t, J = 14.8 Hz, 3 H), 1.38-1.48 (m, 2 H), 1.69-1.77 (m, 2 H), 2.75-2.79 (t, J = 15.6 Hz, 2 H), 7.31-7.35 (t, J = 14.8 Hz,
1 H), 7.42-7.46 (t, J = 15.2 Hz, 2 H), 7.59-7.61 (d, J = 8.8 Hz, 2 H), 7.83 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 22.5, 26.7, 30.8, 125.6, 127.8, 128.7, 129.0, 135.8, 145.3, 149.1. GC-MS (ES): m/z = 201 [M]⁺.
Compound 7b: ^¹H NMR (400 MHz, CDCl₃): δ = 0.92-0.96 (m, 3 H), 1.37-1.46 (m, 2 H), 1.68-1.75 (m, 2 H), 2.71-2.75 (t, J = 15.2 Hz, 2 H), 3.84 (s, 3 H), 6.96-6.98 (m, 2 H), 7.51-7.53 (m, 2 H), 7.80 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃):
δ = 13.9, 22.5, 26.6, 30.9, 55.3, 114.3, 121.7, 130.1, 130.1, 134.4, 145.4, 148.7, 159.3. GC-MS (ES): m/z = 231 [M]⁺.
Compound 7c: ^¹H NMR (400 MHz, CDCl₃): δ = 0.92-0.96 (t, J = 14.8 Hz, 3 H), 1.37-1.47 (m, 2 H), 1.68-1.76 (m, 2 H), 2.38 (s, 3 H), 2.73-2.77 (t, J = 15.2 Hz, 2 H), 7.23-7.25 (d, J = 8.0 Hz, 2 H), 7.48-7.50 (d, J = 8.0 Hz, 2 H), 7.81 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 21.2, 22.5, 26.7, 30.9, 125.7, 126.2, 129.5, 135.2, 137.8, 145.5, 148.9. GC-MS (ES): m/z = 215 [M]⁺.
Compound 7d: ^¹H NMR (400 MHz, CDCl₃): δ = 0.92-0.96 (t, J = 14.8 Hz, 3 H), 1.36-1.46 (m, 2 H), 1.67-1.75 (m, 2 H), 2.71-2.74 (t, J = 15.2 Hz, 2 H), 7.10-7.16 (m, 2 H), 7.53-7.58 (m, 2 H), 7.81 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃):
δ = 13.9, 22.5, 26.6, 30.8, 115.8, 116.0, 125.2, 125.2, 127.5, 135.5, 135.5, 144.6, 149.1, 161.0, 163.5. GC-MS (ES): m/z = 219 [M]⁺.
Compound 7e: ^¹H NMR (400 MHz, CDCl₃): δ = 0.93-0.96 (t, J = 14.8 Hz, 3 H), 1.39-1.44 (m, 2 H), 1.68-1.74 (m, 2 H), 2.72-2.76 (t, J = 5.6 Hz, 2 H), 7.45-7.47 (d, J = 8.8 Hz, 2 H), 7.56-7.58 (d, J = 8.4 Hz, 2 H), 7.84 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 22.5, 26.7, 30.7, 121.8, 127.1, 127.9, 128.1, 132.0, 136.4, 144.4, 149.3. GC-MS (ES):
m/z = 279 [M]⁺.
Compound 7f: ^¹H NMR (400 MHz, CDCl₃): δ = 0.85-0.89 (t, J = 14.4 Hz, 3 H), 1.29-1.35 (m, 2 H), 1.61-1.67 (m, 2 H), 2.51-2.55 (t, J = 15.2 Hz, 2 H), 7.33-7.39 (m, 3 H), 7.49-7.51 (m, 1 H), 7.91 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃):
δ = 13.8, 22.3, 25.7, 30.6, 126.7, 127.9, 130.2, 130.5, 131.8, 134.2, 137.9, 143.4, 150.2. GC-MS (ES): m/z = 235 [M]⁺.
Compound 7g: ^¹H NMR (400 MHz, CDCl₃): δ = 0.94-0.97 (t, J = 14.8 Hz, 3 H), 1.38-1.47 (m, 2 H), 1.69-1.77 (m, 2 H), 2.75-2.78 (t, J = 15.2 Hz, 2 H), 7.29-7.31 (m, 1 H), 7.35-7.39 (t, J = 15.6 Hz, 1 H), 7.46-7.49 (m, 1 H), 7.59-7.60 (t, J = 3.6 Hz, 1 H), 7.84 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.4, 22.5, 26.7, 30.7, 123.6, 125.6, 127.8, 130.0, 130.6, 134.8, 136.9, 144.1, 149.4. GC-MS (ES): m/z = 235 [M]⁺.
Compound 7h: ^¹H NMR (400 MHz, CDCl₃): δ = 0.93-0.96 (t, J = 14.8 Hz, 3 H), 1.39-1.45 (m, 2 H), 1.68-1.76 (m, 2 H), 2.72-2.76 (t, J = 15.2 Hz, 2 H), 7.39-7.42 (m, 2 H), 7.51-7.53 (m, 2 H), 7.83 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃):
δ = 13.9, 22.5, 26.7, 30.7, 126.8, 127.4, 129.0, 129.4, 129.4, 133.7, 136.3, 144.4, 149.2. GC-MS (ES): m/z = 235 [M]⁺.
Compound 7i: ^¹H NMR (400 MHz, CDCl₃): δ = 0.95-0.99 (t, J = 14.8 Hz, 3 H), 1.42-1.48 (m, 2 H), 1.72-1.78 (m, 2 H), 2.82-2.86 (t, J = 15.6 Hz, 2 H), 7.77-7.79 (m, 2 H), 7.93 (s, 1 H), 8.30-8.32 (m, 2 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 22.5, 27.1, 30.6, 124.3, 125.7, 128.1, 129.8, 134.9, 139.6, 143.5, 146.7, 150.3. GC-MS (ES): m/z = 246 [M]⁺.
Compound 7j: ^¹H NMR (400 MHz, CDCl₃): δ = 0.82-0.86 (t, J = 14.8 Hz, 3 H), 1.26-1.35 (m, 2 H), 1.63-1.71 (m, 2 H), 2.55-2.59 (t, J = 15.6 Hz, 2 H), 7.50-7.56 (m, 4 H), 7.83-7.85 (m, 1 H), 7.89-7.95 (m, 2 H), 8.00 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.8, 22.4, 25.9, 31.0, 125.1, 125.5, 126.0, 126.3, 126.7, 128.4, 128.5, 129.8, 131.9, 133.8, 137.8, 145.2, 150.2. GC-MS (ES): m/z = 251 [M]⁺.
Compound 7k: ^¹H NMR (400 MHz, CDCl₃): δ = 0.93-0.97 (t, J = 14.8 Hz, 3 H), 1.34-1.43 (m, 2 H), 1.63-1.71 (m, 2 H), 2.60-2.63 (t, J = 4.8 Hz, 2 H), 6.85-6.89 (d, J = 16.4 Hz,
1 H), 6.99-7.03 (d, J = 16.4 Hz, 1 H), 7.26-7.29 (t, J = 12.0 Hz, 1 H), 7.34-7.38 (t, J = 15.2 Hz, 2 H), 7.47-7.49 (d, J = 7.6 Hz, 2 H), 7.77 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃):
δ = 13.8, 13.9, 22.3, 31.0, 31.1, 112.5, 112.5, 126.4, 128.0, 128.0, 128.3, 128.4, 128.8, 128.8, 136.7, 136.7, 137.7, 145.1, 149.4, 149.4. GC-MS (ES): m/z = 227 [M]⁺.
Compound 7l: ^¹H NMR (400 MHz, CDCl₃): δ = 0.90-0.94 (t, J = 14.4 Hz, 3 H), 1.33-1.43 (m, 2 H), 1.64-1.71 (m, 2 H), 2.75-2.79 (t, J = 15.2 Hz, 2 H), 6.47-6.48 (m, 1 H), 6.54-6.54 (d, J = 3.2 Hz, 1 H), 7.47 (s, 1 H), 7.76 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.8, 22.3, 25.8, 30.8, 107.1, 111.3, 136.0, 138.6, 142.4, 149.0. GC-MS (ES): m/z = 191 [M]⁺.
Compound 7m: ^¹H NMR (400 MHz, CDCl₃): δ = 0.87-0.93 (m, 9 H), 1.28-1.34 (m, 2 H), 1.53-1.59 (m, 2 H), 1.88-1.95 (m, 1 H), 2.37-2.43 (m, 4 H), 7.65 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 22.3, 22.4, 25.3, 28.1, 31.2, 33.5, 135.0, 146.5, 148.9. GC-MS (ES): m/z = 181 [M]⁺.
Compound 7n: ^¹H NMR (400 MHz, CDCl₃): δ = 0.89-0.92 (t, J = 14.4 Hz, 3 H), 1.26-1.35 (m, 6 H), 1.50-1.59 (m, 4 H), 1.70-1.83 (m, 4 H), 2.42-2.49 (m, 2 H), 2.60-2.66 (m, 1 H), 7.64 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.9, 22.3, 25.3, 25.8, 26.3, 31.5, 31.7, 34.8, 132.7, 148.5, 151.1. GC-MS (ES): m/z = 207 [M]⁺.
Compound 7o: ^¹H NMR (400 MHz, CDCl₃): δ = 1.31-1.35 (t, J = 15.2 Hz, 3 H), 2.78-2.84 (m, 2 H), 7.32-7.35 (t, J = 14.8 Hz, 1 H), 7.41-7.46 (m, 2 H), 7.59-7.61 (d, J = 7.6 Hz, 2 H), 7.84 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.1, 20.3, 125.7, 127.9, 128.8, 128.9, 136.9, 145.1, 149.2. GC-MS (ES): m/z = 173 [M]⁺.
Compound 7p: ^¹H NMR (400 MHz, CDCl₃): δ = 4.15 (s,
2 H), 7.19-7.28 (m, 4 H), 7.30-7.35 (m, 2 H), 7.40-7.43 (m, 2 H), 7.59-7.62 (m, 2 H), 7.87 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 32.9, 125.9, 126.5, 128.3, 125.5, 128.5, 128.6, 128.9, 133.9, 138.6, 146.6, 149.5. GC-MS (ES): m/z = 235 [M]⁺.
Compound 7q: ^¹H NMR (400 MHz, CDCl₃): δ = 0.89-0.92 (t, J = 14.8 Hz, 3 H), 1.58-1.67 (m, 2 H), 2.55-2.59 (t, J = 14.8 Hz, 2 H), 3.82 (s, 1 H), 7.11-7.22 (m, 4 H), 7.24-7.30 (m, 1 H), 7.70 (s, 2H). ^¹³C NMR (100 MHz, CDCl₃): δ = 13.6, 21.6, 26.5, 32.1, 126.3, 128.5, 128.6, 133.2, 139.3, 148.0, 149.1. GC-MS (ES): m/z = 235 [M]⁺.
Compound 7r: ^¹H NMR (400 MHz, CDCl₃): δ = 3.53-3.54 (d, J = 6.0 Hz, 2 H), 5.12-5.14 (m, 1 H), 5.17 (s, 1 H), 6.00-6.10 (m, 1 H), 7.30-7.34 (t, J = 14.4 Hz, 1 H), 7.40-7.44 (t, J = 15.2 Hz, 2 H), 7.58-7.60 (d, J = 8.0 Hz, 2 H), 7.84 (s,
1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 31.4, 116.6, 125.8, 128.2, 128.6, 128.8, 133.1, 134.4, 146.2, 149.4. GC-MS (ES): m/z = 185 [M]⁺.
Compound 7s: ^¹H NMR (400 MHz, CDCl₃): δ = 0.85-0.88 (t, J = 13.6 Hz, 3 H), 1.27 (s, 6 H), 1.55-1.60 (m, 2 H), 2.57-2.61 (t, J = 14.8 Hz, 2 H), 3.21-3.23 (d, J = 6.4 Hz, 2 H), 5.05-5.11 (m, 2 H), 5.87-5.96 (m, 1 H), 7.69 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 14.0, 22.5, 24.4, 28.1, 28.7, 30.2, 31.4, 116.0, 131.9, 135.2, 147.9, 148.9. GC-MS (ES): m/z = 193 [M]⁺.
Compound 7t: ^¹H NMR (400 MHz, CDCl₃): δ = 1.32-1.34 (t, J = 6.8 Hz, 6 H), 3.23-3.30 (m, 1 H), 7.32-7.36 (t, J = 15.2 Hz, 1 H), 7.43-7.46 (t, J = 15.2 Hz, 2 H), 7.57-7.60 (t, J = 8.4 Hz, 2 H) 7.84 (s, 1 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 22.0, 25.7, 126.1, 128.0, 128.8, 129.0, 140.9, 144.2, 149.4. GC-MS (ES): m/z = 187 [M]⁺.
Compound 8a: ^¹H NMR (400 MHz, CDCl₃): δ = 0.90-0.94 (t, J = 14.8 Hz, 6 H), 1.29-1.36 (m, 4 H), 1.38-1.46 (m, 2 H), 1.49-1.55 (m, 2 H), 1.88-2.05 (m, 4 H), 2.48 (s, 3 H), 7.40-7.42 (d, J = 8.0 Hz, 2 H), 7.85-7.87 (d, J = 8.4 Hz, 2 H).

Supplementary Material

Supporting Information